Core Insights - illumin Holdings Inc. has launched a new Forecasting tool aimed at enhancing marketers' ability to plan and execute advertising campaigns with greater confidence and clarity [1][3] Product Features - The Forecasting tool is fully integrated within the illumin platform, providing a comprehensive, data-driven view of campaign potential prior to launch [2] - Unlike other platforms, illumin allows for simultaneous planning across multiple tactics and channels, including CTV, DOOH, and native advertising, while offering granular control over each media element [2] - The tool enables marketers to model the impact of individual media elements and consolidate them into a cohesive campaign forecast, offering clarity on audience reach, spend allocation, and strategic performance [2] Strategic Importance - The launch of the Forecasting tool reflects illumin's commitment to transforming programmatic advertising by equipping marketers with essential tools and insights for success in a data-driven media landscape [3] - The tool introduces flexibility and foresight into the planning process, empowering marketing teams to proceed with confidence [3] Company Overview - illumin is focused on evolving the digital advertising landscape by providing a customer-centric approach that allows brands and agencies to plan, build, and execute campaigns across various marketing channels within a single platform [4] - The company serves clients across North America, Latin America, and Europe, emphasizing a unified approach to digital advertising [4]

Core Insights - Alumis Inc. has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, targeting moderate-to-severe plaque psoriasis, with over 1,700 patients enrolled [2][4] - Topline results are expected to be reported in early Q1 2026, indicating progress towards providing new treatment options for patients [1][2] - ESK-001 is a next-generation oral TYK2 inhibitor designed to address immune dysregulation in various diseases, including plaque psoriasis [3][7] Clinical Program Details - The ONWARD clinical program consists of two parallel global Phase 3 trials, ONWARD1 and ONWARD2, each lasting 24 weeks and designed to evaluate the efficacy and safety of ESK-001 [4][5] - Patients are randomized in a 2:1:1 ratio to receive either ESK-001 40 mg twice daily, placebo, or apremilast, with co-primary endpoints focusing on the Psoriasis Area and Severity Index (PASI 75) and sPGA score [4][5] - An optional long-term extension trial, ONWARD3, is ongoing to assess the durability and long-term safety of ESK-001 for patients completing Week 24 [5] Product Profile - ESK-001 is characterized as a highly selective oral TYK2 inhibitor, aiming to minimize off-target effects while providing effective treatment for immune-mediated diseases [3][7] - The drug's development is supported by positive data from the Phase 2 STRIDE clinical trial and ongoing long-term open-label extensions [5] Broader Development Pipeline - Alumis is also exploring ESK-001's potential in other immune-mediated conditions, including a Phase 2b trial for systemic lupus erythematosus [6][7] - The company is developing a once-daily modified-release formulation of ESK-001 to enhance patient convenience compared to the current twice-daily regimen [5]

Core Insights - VCI Global Limited is developing Project QG, a next-generation infrastructure platform aimed at enabling sovereign AI deployment and encrypted data monetization for governments and institutions [1][4] - The global AI market is projected to exceed US$1.8 trillion by 2030, driven by enterprise adoption and the growth of AI-native infrastructure [2] - The cybersecurity and data protection market is expected to reach approximately US$298.5 billion by 2028, indicating a growing demand for secure data solutions [3] Project QG Overview - Project QG integrates AI-driven hardware encryption, zero-trust computing, and blockchain validation, positioning it as a foundational layer for future AI and data sovereignty [2] - The platform is designed for institutions that require sovereign-ready infrastructure to comply with data localization laws while maintaining control over their information [4] - VCI Global is currently engaging institutional stakeholders for early proof-of-concept pilots, with a full launch planned for Q3 2025 [5] Strategic Importance - The initiative addresses the underutilization of institutional and national datasets due to regulatory risks and privacy concerns, aiming to unlock value from sensitive data without compromising its integrity [6] - The convergence of AI, cybersecurity, and sovereign data economics places VCI Global at the forefront of this emerging market [4] - The company emphasizes the importance of monetizing proprietary data and software assets as a new revenue stream for enterprises [3]

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors (“Board”). Dr. C ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to ...

Highlights: Diamond drilling is targeting Mine Centre and the highly prolific gold veins surrounding the historic Foley Mine in Northern Ontario.Drilling permits are expected by Mid June with drilling to commence before the end on the monthFollowing drill results, work will begin towards delivering a NI 43-101 compliant resource estimate in the first half of 2026 TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Q-Gold Resources Ltd (TSXV: QGR, OTC: QGLDF) has announced its 2025 exploration strategy for the Mine C ...

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present a company overview at the Jefferies 2025 Global Healthcare Conference on Thursday, June 5, 2025 at 2 p.m. ET. A live webcast will be available in the Invest ...

SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancin ...

In partnership with project Champions, AT&T, Bell, stc, TELUS, GCI and Acronym Solutions, the TM Forum Catalyst project demonstrates how telecom operators can evolve APIs into scalable, high-quality, on-demand services to unlock powerful new revenue opportunities.TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Optiva Inc. (TSX:OPT), a global leader in BSS software for the telecommunications industry, PlektonLabs, a trusted leading system integrator serving global telecom industry and Qeema, a leading ICT solution ...

TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Canadian Life Companies Split Corp. (the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has accepted its notice of intention to make a Normal Course Issuer Bid (the “NCIB”) to purchase its Preferred Shares and Class A Shares through the facilities of the TSX and/or alternative Canadian trading systems. The NCIB will commence on June 2, 2025 and terminate on June 1, 2026. Pursuant to the NCIB, the Company proposes to purchase, from time to tim ...